Genome-wide association study suggests four variants influencing outcomes with ranibizumab therapy in exudative age-related macular degeneration

Masato Akiyama, Atsushi Takahashi, Yukihide Momozawa, Satoshi Arakawa, Fuyuki Miya, Tatsuhiko Tsunoda, Kyota Ashikawa, Yuji Oshima, Miho Yasuda, Shigeo Yoshida, Hiroshi Enaida, Xue Tan, Yasuo Yanagi, Tsutomu Yasukawa, Yuichiro Ogura, Yoshimi Nagai, Kanji Takahashi, Kimihiko Fujisawa, Maiko Inoue, Akira ArakawaKoji Tanaka, Mitsuko Yuzawa, Kazuaki Kadonosono, Koh Hei Sonoda, Tatsuro Ishibashi, Michiaki Kubo

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

To identify factors associated with ranibizumab responses in patients with exudative age-related macular degeneration (AMD), we performed a genome-wide association study (GWAS) and a replication study using a total of 919 exudative AMD patients treated with intravitreal ranibizumab in a Japanese population. In the combined analysis of GWAS and the replication study, no loci reached genome-wide significant level; however, we found four variants showed suggestive level of associations with visual loss at month three (rs17822656, rs76150532, rs17296444, and rs75165563: Pcombined < 1.0 × 10−5). Of the candidate genes within these loci, three were relevant to VEGF-related pathway (KCNMA1, SOCS2, and OTX2). The proportions of patients who worsened visual acuity were 13.7%, 38.8%, 58.0%, and 80.0% in patients with 0, 1, 2, and 3 or more identified risk variants, respectively. Changes in visual acuity decreased linearly as the number of risk variants increased (P = 1.67 × 10–12). The area under the curve using age, baseline visual acuity, and history of previous treatment was 0.607, and improved significantly to 0.713 in combination with identified variants (P < 0.0001). Although further study is needed to confirm their associations, our results offer candidate variants influencing response to ranibizumab therapy.

Original languageEnglish
Pages (from-to)1083-1091
Number of pages9
JournalJournal of Human Genetics
Volume63
Issue number10
DOIs
Publication statusPublished - Oct 1 2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Genome-wide association study suggests four variants influencing outcomes with ranibizumab therapy in exudative age-related macular degeneration'. Together they form a unique fingerprint.

Cite this